Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774131 | 0.91 | PDE4B (0.71) | PDE4BPDE4D | |
| SCHEMBL4339561 | 0.90 | PDE4B (0.74) | PDE4BPDE4D | |
| SCHEMBL4330489 | 0.89 | PDE4B (0.88) | PDE4BPDE4D | |
| SCHEMBL4337594 | 0.88 | PDE4B (0.86) | PDE4BPDE4D | |
| SCHEMBL2773333 | 0.88 | PDE4B (0.67) | PDE4BPDE4D | |
| SCHEMBL583135 | 0.87 | PDE4B (0.77) | PDE4BPDE4D | |
| SCHEMBL4337200 | 0.86 | PDE4B (0.74) | PDE4BPDE4D | |
| SCHEMBL13870235 | 0.86 | PDE4B (0.65) | PDE4BPDE4D | |
| SCHEMBL4332749 | 0.86 | PDE4B (0.82) | PDE4BPDE4D | |
| SCHEMBL14115774 | 0.86 | PDE4B (0.77) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581532-B1 | PYRAZOLO¬3,4-B PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2010-04-28 | — | — | EP | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
| EP-1581532-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056823-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4D 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.